MX2022001906A - Inmunotolerancia dirigida con un agonista de la proteina de muerte programada 1 (pd-1). - Google Patents

Inmunotolerancia dirigida con un agonista de la proteina de muerte programada 1 (pd-1).

Info

Publication number
MX2022001906A
MX2022001906A MX2022001906A MX2022001906A MX2022001906A MX 2022001906 A MX2022001906 A MX 2022001906A MX 2022001906 A MX2022001906 A MX 2022001906A MX 2022001906 A MX2022001906 A MX 2022001906A MX 2022001906 A MX2022001906 A MX 2022001906A
Authority
MX
Mexico
Prior art keywords
agonist
immunotolerance
targeted
targeted immunotolerance
polypeptides
Prior art date
Application number
MX2022001906A
Other languages
English (en)
Inventor
Joanne L Viney
Lauren Schwimmer
Nathan Higginson-Scott
Jacob Glanville
Kevin Lewis Otipoby
Salvatore Alioto
Lindsay J Edwards
David Maurer
Sarah Ives
Sawsan Youssef
Devanshi Shanghavi
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of MX2022001906A publication Critical patent/MX2022001906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos y polipéptidos para conferir privilegio inmunológico específico de sitio o local.
MX2022001906A 2019-08-19 2020-08-19 Inmunotolerancia dirigida con un agonista de la proteina de muerte programada 1 (pd-1). MX2022001906A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888694P 2019-08-19 2019-08-19
US202063027449P 2020-05-20 2020-05-20
PCT/US2020/046920 WO2021034890A1 (en) 2019-08-19 2020-08-19 Targeted immunotolerance with a pd-1 agonist

Publications (1)

Publication Number Publication Date
MX2022001906A true MX2022001906A (es) 2022-03-17

Family

ID=74660675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001906A MX2022001906A (es) 2019-08-19 2020-08-19 Inmunotolerancia dirigida con un agonista de la proteina de muerte programada 1 (pd-1).

Country Status (11)

Country Link
US (1) US20210206856A1 (es)
EP (1) EP4017595A4 (es)
JP (1) JP2022544990A (es)
KR (1) KR20220050168A (es)
CN (1) CN114728179A (es)
AU (1) AU2020333757A1 (es)
BR (1) BR112022003163A2 (es)
CA (1) CA3148329A1 (es)
MX (1) MX2022001906A (es)
TW (1) TW202124437A (es)
WO (1) WO2021034890A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
TW202110885A (zh) * 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
US20210187027A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
KR20230048144A (ko) * 2020-08-19 2023-04-10 팬디온 오퍼레이션스, 인코포레이티드 다중-파라토프 항-pd-1 항체 및 그의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP3018142A1 (en) * 2006-06-06 2016-05-11 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
KR101687032B1 (ko) * 2008-05-07 2016-12-15 아고스 쎄라퓨틱스, 인코포레이티드 인간 인터페론-알파에 대한 인간화 항체
JP2013521324A (ja) * 2010-03-10 2013-06-10 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
JP2012053508A (ja) * 2010-08-31 2012-03-15 Mitsubishi Heavy Ind Ltd 数値制御工作機械
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
WO2015179799A1 (en) * 2014-05-22 2015-11-26 The General Hospital Corporation DD1alpha RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS
CN113527495A (zh) * 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
US10548987B2 (en) * 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
JP2018535655A (ja) * 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
KR20230118713A (ko) * 2016-06-03 2023-08-11 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
AU2018234810B2 (en) * 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
KR20200084320A (ko) * 2017-08-18 2020-07-10 그릿스톤 온콜로지, 인코포레이티드 공유 항원을 표적으로 하는 항원-결합 단백질
KR20200097275A (ko) * 2017-12-06 2020-08-18 팬디온 테라퓨틱스, 인코포레이티드 Il-2 뮤테인 및 그 용도
WO2021168192A2 (en) * 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins

Also Published As

Publication number Publication date
TW202124437A (zh) 2021-07-01
WO2021034890A1 (en) 2021-02-25
CA3148329A1 (en) 2021-02-25
JP2022544990A (ja) 2022-10-24
KR20220050168A (ko) 2022-04-22
CN114728179A (zh) 2022-07-08
EP4017595A1 (en) 2022-06-29
BR112022003163A2 (pt) 2022-05-17
AU2020333757A1 (en) 2022-03-24
US20210206856A1 (en) 2021-07-08
EP4017595A4 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
MX2022001906A (es) Inmunotolerancia dirigida con un agonista de la proteina de muerte programada 1 (pd-1).
MX2019013517A (es) Inmunotolerancia dirigida.
MX2020010379A (es) Sistemas y metodos de procesamiento.
IL276340A (en) PD-1 agonistic antibodies and their uses
WO2018075820A3 (en) Cereblon-based heterodimerizable chimeric antigen receptors
MX2019007020A (es) Anticuerpos il-11.
SG11202005500TA (en) Method and apparatus for sorting text report categories
MX2020005583A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este.
SG11201811571WA (en) Discharge device and method for manufacturing same
EP3625154A4 (en) ADJUSTABLE CONVEYOR GUIDE RAIL AND RELATED PROCEDURES
EP3782498A4 (en) ROPE ADJUSTING DEVICE AND ARTICLE HAVING A ROPE ADJUSTING DEVICE
MX2020002070A (es) Receptores solubles de interferon y usos de los mismos.
MX2017016408A (es) Sujetador de resorte para transportador de alto angulo.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
PL3941060T3 (pl) Sposób i urządzenie inter-predykcji oparte na dmvr i bdof
EP3928331C0 (en) SYSTEMS AND METHODS FOR DEPOSITION OF HAZARDOUS MATERIALS
SG11202007259TA (en) Conveying and sorting apparatus
IL277728A (en) Bioxomes particles, redoxomes, method and composition
MX2019011297A (es) Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
EP3892572A4 (en) DIRECT ADVANCE FEED DEVICE AND COMBINATION WEIGHTING DEVICE PROVIDED WITH THE SAME SYSTEM
SG11202101349SA (en) Gas distribution assemblies and operation thereof
SG11202007248RA (en) Conveying and sorting apparatus
SG10201806014TA (en) Feedback canceller and hearing aid
MX2018013001A (es) Aparato de montaje con engranajes.
EP4081354C0 (de) Sortiervorrichtung und -verfahren